The company’s pipeline focuses on novel mechanisms with potential best-in-class profiles. As shown in the following comprehensive pipeline overview, Arcus has positioned its assets to address ...
Revolution Medicines Inc (NASDAQ:RVMD) presented its corporate update in August 2025, showcasing significant progress in its RAS inhibitor oncology portfolio. The company’s stock has been volatile ...